Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary Phillips

Showing results (121-130 of 136) with videos related to

Pageof 14
Sort By:
Journal of Medicinal Chemistry|July 18, 2018
Atropisomerism by Design: Discovery of a Selective and Stable Phosphoinositide 3-Kinase (PI3K) β InhibitorJayaraman Chandrasekhar, Ryan Dick, Joshua Van Veldhuizen, et al.
Bioorganic & Medicinal Chemistry Letters|November 24, 2016
Selectivity switch between FAK and Pyk2: Macrocyclization of FAK inhibitors improves Pyk2 potencyJulie Farand, Nicholas Mai, Jayaraman Chandrasekhar, et al.
ACS Medicinal Chemistry Letters|June 20, 2020
Discovery of an Atropisomeric PI3Kβ Selective Inhibitor through Optimization of the Hinge Binding MotifStephane Perreault, Fatima Arjmand, Jayaraman Chandrasekhar, et al.
Paediatric and Perinatal Epidemiology|May 21, 2015
Birthweight and Childhood Cancer: Preliminary Findings from the International Childhood Cancer Cohort Consortium (I4C)Ora Paltiel, Gabriella Tikellis, Martha Linet, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 10, 2006
High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantationWilliam Blum, Brian J Bolwell, Gary Phillips, et al.
Bioorganic & Medicinal Chemistry Letters|September 12, 2018
Discovery of selective urokinase plasminogen activator (uPA) inhibitors as a potential treatment for multiple sclerosisImadul Islam, Shendong Yuan, Christopher W West, et al.
Alternatives to Laboratory Animals : ATLA|June 4, 2016
Assessment of in vitro COPD models for tobacco regulatory science: Workshop proceedings, conclusions and paths forward for in vitro model useHolger Behrsing, Hans Raabe, Joseph Manuppello, et al.
Journal of Medicinal Chemistry|May 31, 2002
Design, synthesis, and activity of a novel series of factor Xa inhibitors: optimization of arylamidine groupsGary Phillips, William J Guilford, Brad O Buckman, et al.
Journal of Medicinal Chemistry|January 21, 2017
Discovery of a Phosphoinositide 3-Kinase (PI3K) β/δ Inhibitor for the Treatment of Phosphatase and Tensin Homolog (PTEN) Deficient Tumors: Building PI3Kβ Potency in a PI3Kδ-Selective Template by Targeting Nonconserved Asp856Stephane Perreault, Jayaraman Chandrasekhar, Zhi-Hua Cui, et al.
The Journal of Nutrition|February 3, 2012
Oral tocotrienols are transported to human tissues and delay the progression of the model for end-stage liver disease score in patientsViren Patel, Cameron Rink, Gayle M Gordillo, et al.
Pageof 14

Showing results (121-130 of 136) with videos related to

Sort By:
Pageof 14
Journal of Medicinal Chemistry|July 18, 2018
Atropisomerism by Design: Discovery of a Selective and Stable Phosphoinositide 3-Kinase (PI3K) β InhibitorJayaraman Chandrasekhar, Ryan Dick, Joshua Van Veldhuizen, et al.
Bioorganic & Medicinal Chemistry Letters|November 24, 2016
Selectivity switch between FAK and Pyk2: Macrocyclization of FAK inhibitors improves Pyk2 potencyJulie Farand, Nicholas Mai, Jayaraman Chandrasekhar, et al.
ACS Medicinal Chemistry Letters|June 20, 2020
Discovery of an Atropisomeric PI3Kβ Selective Inhibitor through Optimization of the Hinge Binding MotifStephane Perreault, Fatima Arjmand, Jayaraman Chandrasekhar, et al.
Paediatric and Perinatal Epidemiology|May 21, 2015
Birthweight and Childhood Cancer: Preliminary Findings from the International Childhood Cancer Cohort Consortium (I4C)Ora Paltiel, Gabriella Tikellis, Martha Linet, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 10, 2006
High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantationWilliam Blum, Brian J Bolwell, Gary Phillips, et al.
Bioorganic & Medicinal Chemistry Letters|September 12, 2018
Discovery of selective urokinase plasminogen activator (uPA) inhibitors as a potential treatment for multiple sclerosisImadul Islam, Shendong Yuan, Christopher W West, et al.
Alternatives to Laboratory Animals : ATLA|June 4, 2016
Assessment of in vitro COPD models for tobacco regulatory science: Workshop proceedings, conclusions and paths forward for in vitro model useHolger Behrsing, Hans Raabe, Joseph Manuppello, et al.
Journal of Medicinal Chemistry|May 31, 2002
Design, synthesis, and activity of a novel series of factor Xa inhibitors: optimization of arylamidine groupsGary Phillips, William J Guilford, Brad O Buckman, et al.
Journal of Medicinal Chemistry|January 21, 2017
Discovery of a Phosphoinositide 3-Kinase (PI3K) β/δ Inhibitor for the Treatment of Phosphatase and Tensin Homolog (PTEN) Deficient Tumors: Building PI3Kβ Potency in a PI3Kδ-Selective Template by Targeting Nonconserved Asp856Stephane Perreault, Jayaraman Chandrasekhar, Zhi-Hua Cui, et al.
The Journal of Nutrition|February 3, 2012
Oral tocotrienols are transported to human tissues and delay the progression of the model for end-stage liver disease score in patientsViren Patel, Cameron Rink, Gayle M Gordillo, et al.
Pageof 14